WB, IP
H
Endogenous
19
Rabbit
#O15304
10572
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:50 |
Storage
Specificity / Sensitivity
Species Reactivity:
Human
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro71 of human Siva-1 protein. Antibodies are purified by protein A and peptide affinity chromatography.
Background
First identified as a pro-apoptotic protein that binds the cytoplasmic tail of the TNF receptor superfamily member CD27 (1), Siva-1 also binds several other TNFR family members including glucocorticoid-induced tumor necrosis factor receptor (GITR) and OX40 (1-3), as well as anti-apoptotic Bcl-2 family members Bcl-xL and Bcl-2 (4,5). Siva-1 is composed of a central death domain homology region, a C-terminal box-B-like ring finger followed by a zinc finger-like domain, and a unique N-terminal amphipathic helical region (SAH) (1,4). Studies have demonstrated that Siva-1 has the ability to induce cell death via both the extrinsic and intrinsic apoptotic pathways (1-8). The SAH domain of Siva-1 is responsible for the inhibition of the pro-survival activities of Bcl-xL and Bcl-2, leading to caspase-mediated cell death (4,5,8). Siva-1 plays a role in T cell signaling and homeostasis by inhibiting NF-κB activity, also resulting in apoptotic cell death (7,9). An alternative splice variant of Siva-1, Siva-2, lacks part of the SAH and death domains and is less effective at inducing apoptosis (1,2,5,8). Studies in xenografts have shown that down-regulation of Siva-1 inhibits tumorigenesis in response to p53 activation (10). Down-regulation of Siva-1 may also play a role in tumor metastasis through its regulation of the epithelial-mesenchymal transition (EMT) and cell migration (11). Overexpression of Siva-1 is implicated in several pathological conditions including acute ischemic injury (12) and Coxsackievirus infection (13).
- Prasad, K.V. et al. (1997) Proc Natl Acad Sci U S A 94, 6346-51.
- Yoon, Y. et al. (1999) Oncogene 18, 7174-9.
- Spinicelli, S. et al. (2002) Cell Death Differ 9, 1382-4.
- Xue, L. et al. (2002) Proc Natl Acad Sci U S A 99, 6925-30.
- Chu, F. et al. (2004) Apoptosis 9, 83-95.
- Cao, C. et al. (2001) J Biol Chem 276, 11465-8.
- Gudi, R. et al. (2006) Oncogene 25, 3458-62.
- Py, B. et al. (2004) J Immunol 172, 4008-17.
- Hench, V.K. and Su, L. (2011) BMC Immunol 12, 54.
- Du, W. et al. (2009) Cell Death Differ 16, 1493-504.
- Li, N. et al. (2011) Proc Natl Acad Sci U S A 108, 12851-6.
- Padanilam, B.J. et al. (1998) Kidney Int 54, 1967-75.
- Henke, A. et al. (2000) J Virol 74, 4284-90.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting IP: Immunoprecipitation
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.